Alps Advisors Inc Celldex Therapeutics, Inc. Transaction History

Alps Advisors Inc

$14.1 Billion
Q1 2024

A detailed history of Alps Advisors Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 45,440 shares of CLDX stock, worth $1.63 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

45,440

Previous 37,645 20.71%

Holding current value

$1.63 Million

Previous $1.49 Million 27.73%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$35.22 - $51.88 $274,539 - $404,404	7,795 Added 20.71%	45,440 $1.91 Million
Q4 2023 Feb 14, 2024	BUY	$22.61 - $40.65 $63,240 - $113,698	2,797 Added 8.03%	37,645 $1.49 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $2,875 - $4,232	113 Added 0.33%	34,848 $959,000
Q2 2023 Aug 14, 2023	BUY	$30.29 - $38.28 $109,952 - $138,956	3,630 Added 11.67%	34,735 $1.18 Million
Q1 2023 May 10, 2023	SELL	$34.78 - $47.43 $29,354 - $40,030	-844 Reduced 2.64%	31,105 $1.12 Million

Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $177,486 - $289,932	6,389 Added 25.0%	31,949 $1.42 Million
Q3 2022 Nov 14, 2022	SELL	$22.7 - $37.57 $49,486 - $81,902	-2,180 Reduced 7.86%	25,560 $718,000
Q2 2022 Aug 11, 2022	BUY	$20.5 - $37.33 $568,670 - $1.04 Million	27,740 New	27,740 $748,000
Q2 2021 Aug 11, 2021	SELL	$20.71 - $35.37 $1.48 Million - $2.53 Million	-71,581 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$16.19 - $29.91 $13,939 - $25,752	861 Added 1.22%	71,581 $1.48 Million
Q4 2020 Feb 03, 2021	BUY	$14.99 - $22.75 $1.06 Million - $1.61 Million	70,720 New	70,720 $1.24 Million

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

61.2M

Call Options Held

291K

Put Options Held

246K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.68B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Celldex Therapeutics, Inc. Transaction History